Study IDs Predictors of Late Recurrence in Soft Tissue Sarcomas

Share this content:

the Cancer Therapy Advisor take:

Although recurrence more than 5 years after treatment is uncommon in soft tissue sarcomas, long-term follow-up may be integral to detecting late recurrence in some patients with the disease, according to research published in Cancer.


To identify potential prognostic factors for late recurrence, researchers evaluated follow-up data from patients with localized soft tissue sarcoma from the French Sarcoma Group database from 1990 to 2005. Outcomes included cumulative probabilities of late local and metastatic disease.


They found 719 patients who were alive and had experienced no events more than 5 years after diagnosis, 67 of whom developed late local recurrence and 42 of whom developed late metastatic recurrence. Multivariate analysis suggested that the two factors—internal trunk location and tumor size greater than 100 mm—were independently linked to a higher risk for late local recurrence.


The only factor that was independently associated with an increased risk for late metastatic recurrence, however, was a disease grade greater than 1 according to the French Federation of Cancer Centers Sarcoma group.


The researchers concluded that long-term follow-up is important to finding late local disease recurrence in patients with retroperitoneal or very large soft tissue sarcomas and late metastatic recurrence in those with high-grade disease.

Study IDs Predictors of Late Recurrence in Soft Tissue Sarcomas
Study IDs Predictors of Late Recurrence in Soft Tissue Sarcomas

Late recurrence of soft tissue sarcoma is relatively uncommon. However, the results of the current study emphasize the critical role of long-term follow-up to detect late local local or metastatic disease.

READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs